Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~  * Metastatic or locally recurrent disease~* Not curable with standard therapy~* Systemic chemotherapy is indicated, due to disease progression while receiving androgen-ablative therapy (i.e., hormone-refractory disease)~  * Disease progression is defined as development of new metastatic lesions OR ≥ 2 consecutive rises in prostate-specific antigen (PSA) over a reference value~ * Androgen ablative therapy must have included either medical or surgical castration~    * Castrate level of testosterone (≤ 1.7 nmol/L) required if treated with medical androgen ablation~ * Patients with documented disease progression while on peripheral antiandrogens must also have documented PSA progression after stopping antiandrogens~* PSA ≥ 5 ng/mL~* No known CNS metastases~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* No known bleeding disorder~Hepatic~* PT and PTT or INR normal~* Bilirubin normal~* AST and ALT ≤ 1.5 times upper limit of normal (ULN)~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No significant cardiac dysfunction~Other~* Fertile patients must use effective contraception~* No pre-existing peripheral neuropathy ≥ grade 2~* No active, uncontrolled infection~* No significant neurological disorder that would preclude study compliance~* No history of other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Chemotherapy~* No prior chemotherapy except estramustine and recovered~* No other concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* At least 4 weeks since prior antiandrogens (6 weeks for bicalutamide)~* Luteinizing hormone-releasing hormone (LHRH) agonist therapy must be continued\* or restarted\* during study treatment to maintain castrate levels of testosterone NOTE: \*For patients receiving LHRH agonist therapy prior to study entry~Radiotherapy~* At least 4 weeks since prior external beam radiotherapy except low-dose, nonmyelosuppressive radiotherapy~  * Must have had less than 25% of marrow irradiated~* No prior strontium chloride Sr 89~* No concurrent radiotherapy except low-dose, nonmyelosuppressive, palliative radiotherapy~Surgery~* At least 2 weeks since prior major surgery~Other~* At least 4 weeks since prior investigational agent~* At least 4 weeks since prior anticancer therapy~* No concurrent therapeutic anticoagulants except low-dose oral anticoagulants (i.e., 1 mg warfarin) or low molecular weight heparin~* No other concurrent investigational agents~* No other concurrent cytotoxic therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- OGX011, Docetaxel and Prednisone (Type: ACTIVE_COMPARATOR): None
- Docetaxel plus prednisone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).